Jill Feldman: Excited to share a blog I wrote for Cure Magazine highlighting the Lung Cancer Genetics Study
Jill Feldman, Co-Founder of EGFR Resisters and Lung Cancer Patient and Advocate, shared a post on LinkedIn:
“I am excited to share a blog I wrote for Cure Magazine highlighting the Lung Cancer Genetics Study.
This collaboration between nearly two dozen lung cancer organizations and 23andMe unites patients, advocates, doctors, and researchers to find the genetic risks of lung cancer.
I’m a 3rd generation on both sides of my family to be diagnosed with lung cancer, so my kids are my world and my personal WHY
But this study represents something MUCH bigger: Potential = HOPE:
- Identify genetic variants (change in DNA) to better understand risk factors.
- Improve early detection ability, risk prediction & potential for more effective treatments.
- Unite patients, advocates, & researchers.
- Prioritize data security & patient voices.
This is a rare opportunity to create a large database that isn’t trapped in silos or owned by a single company or institution!
Read more about why this matters and how it can change the future of lung cancer research.
For the first time, the lung cancer community has come together to support a research study, uniting patients, advocates, and organizations in an effort to drive meaningful progress in understanding this disease, predicting who is at risk and developing more and better treatments.
THAT is the power of collaboration and, most importantly, to patients and families, HOPE!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023